COVID-19 Novel Molecular Point of Care Diagnostics Evaluation

NCT06055218 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-10-05

No results posted yet for this study

Summary

Point estimates of sensitivity and specificity of molecular POC platforms for SARS-CoV-2, with 95% confidence intervals, using RT-PCR as reference standard.

Conditions

  • COVID-19 Respiratory Infection

Sponsors & Collaborators

  • Foundation for Innovative New Diagnostics, Switzerland

    lead OTHER

Principal Investigators

  • Camille Escadafal · FIND Diagnostics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2023-04-11
Completion
2023-08-30

Countries

  • Switzerland
  • Uganda
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055218 on ClinicalTrials.gov